|
Diagnostic value of combining serum CA19-9, CA125, CEA, and ferritin with contrast-enhanced CT features for cholangiocarcinoma
|
H. Zhang   , J. Wang , Q. Lu , R. Pei |
| Department of Ultrasound, Anhui No.2 Provincial People's Hospital, Hefei City 230041, Anhui Province, China , wangjj2980@163.com |
|
|
Abstract: (474 Views) |
Background: To probe the diagnostic value of combining serum tumor markers - Cancer Antigen 19-9 (CA19-9), carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA), and Ferritin - with contrast-enhanced computed tomography (CT) for cholangiocarcinoma (CCA). Materials and Methods: A total of 114 patients from Anhui No.2 Provincial People's Hospital from February 2020 to October 2025 were divided into a cholangiocarcinoma group (n=60) and a benign biliary lesion group (n=54). Serum levels of CA19-9, CA125, CEA, alpha-fetoprotein (AFP), and Ferritin were measured in both groups. CT imaging features of patients in both groups were analyzed. Furthermore, the diagnostic value of the serum markers alone, contrast-enhanced CT alone, and their combination was assessed. Results: Serum concentrations of CA19-9, CA125, CEA, and Ferritin were markedly enhanced in the cholangiocarcinoma group compared to the benign group. Cholangiocarcinoma typically presented as circular high-density shadows within the common bile duct or hepatic duct, accompanied by duct wall infiltration, invasion of the common bile duct, hepatic lobe atrophy, and lymph node enlargement. In contrast, benign lesions primarily appeared as circular high-density shadows with minimal duct wall invasion or lymphadenopathy. The combined approach demonstrated superior sensitivity, specificity, and accuracy for identifying cholangiocarcinoma compared to any single method. The area under the curve (AUC) (0.922) for the combined model was higher than the AUC of 0.865 for the serum marker alone. Conclusion: The integration of serum CA19-9, CA125, CEA, and Ferritin with contrast-enhanced CT findings shows promising diagnostic efficacy for cholangiocarcinoma and offers significant insights for evaluating tumor invasiveness. |
|
| Keywords: Cholangiocarcinoma, tomography, CA-19-9 Antigen, arcinoembryonic antigen, ferritins, ROC curve. |
|
|
Full-Text [PDF 700 kb]
(141 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| References |
1. 1. Harrison JM and Visser BC (2024) Cholangiocarcinoma. Surg Clin North Am, 104(6):1281-1293. [ DOI:10.1016/j.suc.2024.04.003] 2. Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME (2023) Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin, 73(2): 198-222. [ DOI:10.3322/caac.21759] 3. Elvevi A, Laffusa A, Scaravaglio M, Rossi RE, et al. (2022) Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Ann Hepatol, 27(5): 100737. [ DOI:10.1016/j.aohep.2022.100737] 4. Jiang G, Zhang W, Wang T, Ding S, et al. (2020) Characteristics of genomic alterations in Chinese cholangiocarcinoma patients. Jpn J Clin Oncol, 50(10): 1117-1125. [ DOI:10.1093/jjco/hyaa088] 5. Silva M, Maddalo M, Leoni E, Giuliotti S, et al. (2021) Integrated prognostication of intrahepatic cholangiocarcinoma by contrast-enhanced computed tomography: the adjunct yield of radiomics. Abdom Radiol, 46(10): 4689-4700. [ DOI:10.1007/s00261-021-03183-9] 6. Xin Q, Lv R, Lou C, Ma Z, et al. (2020) Primary hepatic neuroendocrine carcinoma coexisting with distal cholangiocarcinoma: A case report and review of the literature. Medicine, 99(26): e20854. [ DOI:10.1097/MD.0000000000020854] 7. Komori T, Inoue D, Zen Y, Yoneda N, et al. (2019) CT imaging comparison between intraductal papillary neoplasms of the bile duct and papillary cholangiocarcinomas. Eur Radiol, 29(6): 3132-3140. [ DOI:10.1007/s00330-018-5841-0] 8. Gul-Utku O, Karatay E, Ergul B, Kisa U, et al. (2020) The role of resolvin D1 in the differential diagnosis of the cholangiocarcinoma and benign biliary diseases. Clin Lab, 66(5): 1. [ DOI:10.7754/Clin.Lab.2020.200212] 9. Jiang T, Lyu SC, Zhou L, Wang J, et al. (2021) Carbohydrate antigen 19-9 as a novel prognostic biomarker in distal cholangiocarcinoma. World J Gastrointest Surg, 13(9): 1025-1038. [ DOI:10.4240/wjgs.v13.i9.1025] 10. Barroso Marquez L, Chao Gonzalez L, Samada Suarez M, Rodriguez Rodriguez H, et al. (2022) Endoscopic retrograde cholangiopancreatography and carbohydrate antigen 19-9 in the differential diagnosis of biliary strictures. Rev Esp Enferm Dig, 114(4): 204-207. [ DOI:10.17235/reed.2021.7711/2020] 11. Wang T and Liu J (2025) Combined CA19-9, CA125, and CEA to predict prognosis of patients with intrahepatic cholangiocarcinoma after radical surgery: a retrospective, multi-institutional study. Ann Surg Treat Res, 109(4): 224-234. [ DOI:10.4174/astr.2025.109.4.224] 12. Ramirez-Carmona W, Diaz-Fabregat B, Yuri Yoshigae A, Musa de Aquino A, et al. (2022) Are serum ferritin levels a reliable cancer biomarker? a systematic review and meta-analysis. Nutr Cancer, 74(6): 1917-1926. [ DOI:10.1080/01635581.2021.1982996] 13. Chen L, Hu S, Liu L, He S, et al. (2025) Prognostic value of preoperative serum ferritin in cholangiocarcinoma patients. Sci Rep, 15(1): 44288. [ DOI:10.1038/s41598-025-27989-5] 14. Wang H, Zhu X, Qiu M, Xuan J, et al. (2024) Impact of clinical lymph node status on survival in patients with intrahepatic cholangiocarcinoma undergoing liver resection plus lymphadenectomy. ANZ J Surg, 94(12): 2189-2194. [ DOI:10.1111/ans.19105] 15. Zhang J, Dong W, Li Y, Fu J, Jia N (2023) Prediction of microvascular invasion in combined hepatocellular-cholangiocarcinoma based on preoperative contrast-enhanced CT and clinical data. Eur J Radiol, 163: 110839. [ DOI:10.1016/j.ejrad.2023.110839] 16. Saeheng T, Karbwang J, Na-Bangchang K (2024) Population-pharmacokinetic/pharmacodynamic model of atractylodes lancea (Thunb.) DC. administration in patients with advanced-stage intrahepatic cholangiocarcinoma: a dosage prediction. BMC Complement Med Ther, 24(1): 384. [ DOI:10.1186/s12906-024-04618-8] 17. Matsas A, Stefanoudakis D, Troupis T, Kontzoglou K, et al. (2023) Tumor markers and their diagnostic significance in ovarian cancer. Life, 13(8): 1689. [ DOI:10.3390/life13081689] 18. Lee JW, Lee JH, Park Y, Kwon J, et al. (2021) Prognostic impact of perioperative CA19-9 levels in patients with resected perihilar cholangiocarcinoma. J Clin Med, 10(7): 1345. [ DOI:10.3390/jcm10071345] 19. Luo G, Jin K, Deng S, Cheng H, et al. (2021) Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Biochim Biophys Acta Rev Cancer, 1875(2): 188409. [ DOI:10.1016/j.bbcan.2020.188409] 20. Zhang M, Cheng S, Jin Y, Zhao Y, Wang Y (2021) Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim Biophys Acta Rev Cancer, 1875(2): 188503. [ DOI:10.1016/j.bbcan.2021.188503] 21. Bjorkman K, Mustonen H, Kaprio T, Kekki H, et al. (2021) CA125: A superior prognostic biomarker for colorectal cancer compared to CEA, CA19-9 or CA242. Tumour Biol 43(1): 57-70. [ DOI:10.3233/TUB-200069] 22. Geng J, Jinli S, Guo W, Li H, et al. (2024) Expression and clinical significance of CA125, CA153 and CEA in nipple discharge of breast cancer patients. J Med Biochem, 43(2): 234-242. [ DOI:10.5937/jomb0-45192] 23. Cerrito L, Ainora ME, Borriello R, Piccirilli G, et al. (2023) Contrast-Enhanced Imaging in the Management of Intrahepatic Cholangiocarcinoma: State of Art and Future Perspectives. Cancers (Basel), 15(13): 3393. [ DOI:10.3390/cancers15133393] 24. Vigano L, Zanuso V, Fiz F, Cerri L, Laino ME, et al. (2025) CT-based radiogenomics of intrahepatic cholangiocarcinoma. Dig Liver Dis, 57(1): 118-124. [ DOI:10.1016/j.dld.2024.06.033] 25. Briasoulis A, Lama N, Rempakos A, Theodorakakou F, et al. (2023) Diagnostic and prognostic value of non-late gadolinium enhancement cardiac magnetic resonance parameters in cardiac amyloidosis. Curr Probl Cardiol, 48(4): 101573. [ DOI:10.1016/j.cpcardiol.2022.101573] 26. van der Bruggen W, de Geus-Oei LF, Bosmans B, Slart R, et al. (2023) Review of the role of bone-SPECT/CT in tarsal coalitions. Nucl Med Commun, 44(2): 115-130. [ DOI:10.1097/MNM.0000000000001643] 27. Li C, Xiao J, Wu S, Liu L, et al. (2023) Clinical application of serum-based proteomics technology in human tumor research. Anal Biochem, 663: 115031. [ DOI:10.1016/j.ab.2022.115031] 28. Lu Y, Cao R, Jiao S, Li L, et al. (2024) A novel method of carotid artery wall imaging: black-blood CT. Eur Radiol, 34(4): 2407-2415. [ DOI:10.1007/s00330-023-10247-5] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Zhang H, Wang J, Lu Q, Pei R. Diagnostic value of combining serum CA19-9, CA125, CEA, and ferritin with contrast-enhanced CT features for cholangiocarcinoma. Int J Radiat Res 2026; 24 (3) :699-703 URL: http://ijrr.com/article-1-7211-en.html
|
